SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

                                   (Mark One)

              |X| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934
                  For the quarterly period ended June 30, 2005

                                       OR

  |_| TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934
          From the transition period from ___________ to ____________.


                         Commission File Number 01-28911
                                                --------


                      NATIONAL HEALTHCARE TECHNOLOGY, INC.
                      ------------------------------------
        (Exact name of small business issuer as specified in its charter)


               Colorado                                     91-1869677
        -------------------------------       ---------------------------------
        (State or other jurisdiction of       (IRS Employer Identification No.)
        incorporation or organization)


            1660 Union Street, Suite 200, San Diego, California 92101
                    (Address of principal executive offices)


                                 (619) 398-8470
                           (Issuer's telephone number)


                          20700 Ventura Boulevard, #227
                        Woodland Hills, California 91364
                        --------------------------------
              (Former name, former address and former fiscal year,
                         if changed since last report)

      Check  whether  the issuer (1) filed all  reports  required to be filed by
Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or for such
shorter period that the  registrant was required to file such reports),  and (2)
has been subject to such filing requirements for the past 90 days:

                               Yes |X|   No |_|

As of August 12,  2005,  18,413,546  shares of Common  Stock of the issuer  were
outstanding.

----------

Transitional Small Business Disclosure Format (Check one):  Yes |_|   No |X|


<PAGE>

ITEM 1. FINANCIAL INFORMATION

                      NATIONAL HEALTHCARE TECHNOLOGY, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                                  BALANCE SHEET
                                  June 30, 2005
                                   (Unaudited)


Assets                                                          $            --
                                                                ===============

                      LIABILITIES AND STOCKHOLDERS' DEFICIT

Current liabilities
  Accounts payable:
    Trade                                                       $        72,394
    Crown Partners, Inc.                                                131,016
                                                                ---------------
    Total current liabilities                                           203.410
                                                                ---------------

STOCKHOLDERS' DEFICIT:
  Preferred stock, $.01 par value, 10,000,000 shares
    authorized, no shares issued and outstanding                             --
  Common stock, $.001 par value, 100,000,000 shares
    authorized, 78,571 shares issued and outstanding                         79
  Additional paid in capital                                          1,245,215
  Accumulated deficit                                                (1,448,704)
                                                                ---------------
    Total Stockholders' Deficit                                        (203.410)
                                                                ---------------

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT                     $            --
                                                                ===============


<PAGE>

                      NATIONAL HEALTHCARE TECHNOLOGY, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                            STATEMENTS OF OPERATIONS
             Three and Nine Months Ended June 30, 2005 and 2004 and
               February 29, 1996 (Inception) through June 30, 2005
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                                              Inception
                                        Three Months Ended                     Nine Months Ended             through June
                                             June 30,                               June 30,                     30,
                                      2005               2004               2005               2004              2005
                                ---------------    ---------------     ---------------   ---------------    ---------------
<S>                                      <C>                <C>                 <C>               <C>               <C>
Revenue                         $            --    $            --     $            --   $            --    $         9,578

Expenses:
  Development costs                          --                 --                  --                --          1,264,236
  General and administrative             19,199             14,346              32,459            28,578            207,548
                                ---------------    ---------------     ---------------   ---------------    ---------------
                                         19,199             14,346              32,459            28,578          1,471,784
                                ---------------    ---------------     ---------------   ---------------    ---------------

Net loss before income taxes            (19,199)           (14,346)            (32,459)          (28,578)        (1,462,206)
Other Income                                                                                                         18,302
Income taxes                                 --                 --                  --                --             (4,800)
                                ---------------    ---------------     ---------------   ---------------    ---------------

Net loss                        $       (19,199)   $       (14,346)    $       (32,459)  $       (28,578)   $    (1,448,704)
                                ===============    ===============     ===============   ===============    ===============

Basic net loss per common share $         (0.24)   $         (0.18)    $         (0.41)  $         (0.36)
                                ===============   ================     ===============   ===============

Weighted average shares
   outstanding                           78,571             78,571              78,571            78,571
                                ===============    ===============     ===============   ===============
</TABLE>

<PAGE>

                      NATIONAL HEALTHCARE TECHNOLOGY, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                            STATEMENTS OF CASH FLOWS
                  Nine Months Ended June 30, 2005 and 2004 and
               February 29, 1996 (Inception) through June 30, 2005
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                         Inception
                                                             Nine Months Ended            through
                                                                 June 30,                June 30,
                                                           2005           2004             2005
                                                       ------------    ------------    ------------
<S>                                                    <C>             <C>             <C>
Cash flows from operating activities:
  Net loss                                             $    (32,459)   $    (28,578)   $ (1,448,704)
    Adjustments to reconcile net loss to net cash
    provided by (used in) operating activities:
      Depreciation and amortization                              --              --          22,977
      Common stock issued for settlement of interest
        Expense                                                  --              --          12,900
      Common stock issued for services                           --              --         217,900
      Loss on abandoned assets                                   --              --         111,612
      Gain on sale of assets                                     --              --            (500)
      Income from sale of abandoned assets                       --              --          (9,578)
Changes in operating assets and liabilities
    Accounts payable                                         32,459          28,578         203,410
                                                       ------------    ------------    ------------
        Net cash used in operating activities                    --              --        (889,983)
                                                       ------------    ------------    ------------

Cash flows from investing activities:
  Purchase of property and equipment                             --              --         (87,314)
  Proceeds from the sale of equipment                            --              --          15,078
                                                       ------------    ------------    ------------
        Net cash used in investing activities                    --              --         (72,236)
                                                       ------------    ------------    ------------

Cash flows from financing activities:
  Proceeds from notes payable                                    --              --         217,200
  Payments on notes payable                                      --              --         (20,000)
  Proceeds from the sale of common stock, net                    --              --         755,441
                                                       ------------    ------------    ------------
        Net cash provided by financing activities                --              --         952,641
                                                       ------------    ------------    ------------

Net increase (decrease) in cash and cash equivalents             --              --              --
  Cash at beginning of period                                    --              --              --
                                                       ------------    ------------    ------------
  Cash at end of period                                $         --    $         --    $         --
                                                       ============    ============    ============
</TABLE>

<PAGE>


                      NATIONAL HEALTHCARE TECHNOLOGY, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                          NOTES TO FINANCIAL STATEMENTS
                                   (unaudited)


Note 1 - BASIS OF PRESENTATION

The balance sheet of the Company as of June 30, 2005, the related  statements of
operations for the three months and nine months ended June 30, 2005 and 2004 and
the  statements  of cash flows for the nine months  ended June 30, 2005 and 2004
included in the financial  statements  have been prepared by the Company without
audit.  In the opinion of  management,  the  accompanying  financial  statements
include all adjustments (consisting of normal,  recurring adjustments) necessary
to summarize fairly the Company's  financial position and results of operations.
The  results of  operations  for the three  months  ended June 30,  2005 are not
necessarily  indicative  of the results of  operations  for the full year or any
other interim  period.  The  information  included in this Form 10-QSB should be
read in  conjunction  with  Management's  Discussion  and Analysis and Financial
Statements and notes thereto  included in the Company's  September 30, 2004 Form
10-KSB.

NOTE 2 - SUBSEQUENT EVENT

On June 30, 2005,  the Company  entered into an Exchange  Agreement with Special
Stone Surfaces,  ES3, Inc.  ("Es3") wherein the Company acquired Es3 in exchange
for the issuance of  approximately  19,414,188  shares of the  Company's  common
stock  to  Es3's  shareholders,  Crown  Partners,  Inc.  ("Crown")  and  certain
consultants.  In addition, Es3 will pay a total of $500,000 to Crown in exchange
for Crown  assuming all the debts and  liabilities  of the Company as well as in
satisfaction  of debts owed by the Company to Crown.  $200,000 was paid to Crown
on July 19, 2005. This transaction  closed on July 19, 2005 and the then-current
Board of Directors resigned in favor of directors nominated by Es3.


<PAGE>




ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS


This report contains  forward looking  statements  within the meaning of Section
27A of the  Securities Act of 1933, as amended and Section 21E of the Securities
Exchange  Act of 1934,  as  amended.  When used in this Form  10-QSB,  the words
"anticipate",  "estimate",  "expect",  "project"  and  similar  expressions  are
intended to identify forward-looking  statements. Such statements are subject to
certain risks,  uncertainties and assumptions including the possibility that the
Company's proposed plan of operation will fail to generate  projected  revenues.
Should  one or more of  these  risks or  uncertainties  materialize,  or  should
underlying assumptions prove incorrect,  actual results may vary materially from
those  anticipated,  estimated or projected.  The Company's actual results could
differ  materially from those set forth on the forward  looking  statements as a
result of the risks set forth in the Company's  filings with the  Securities and
Exchange Commission, general economic conditions, and changes in the assumptions
used in making such forward looking statements.

GENERAL

         National  Healthcare  Technology,  Inc. (the  "Company")  was organized
February 29, 1996 as "Patriot Holding  Corporation" and subsequently changed its
name to "National Healthcare Technology,  Inc." on August 26, 1996. Between 1996
and 1999, the Company was  unsuccessful in raising  sufficient  capital to begin
and  complete  a  proposed  double-blind  study of an  intravenous  drug  called
Magkelate.  The Company did raise $1,000,000 which was used to pay its operating
expenses and general and administrative  expenses as well as expenses related to
starting the  double-blind  study.  Following its inability to raise capital and
needing to conserve its financial  resources,  the Company  dismissed all of its
employees in early 1999.  The developer of Magkelate  passed away in the fall of
1999 and the  Magkelate  patent has  expired.  Since 1999,  the Company has been
substantially  inactive.  The Company is in the development  stage as defined in
Statement of Financial Accounting Standards No. 7.

         On June 30, 2005, the Company  entered into an Exchange  Agreement (the
"Exchange Agreement") by and among the Company,  Crown Partners,  Inc., a Nevada
corporation  and at such time, the largest  stockholder  of the Company  ("Crown
Partners"), Special Stone Surfaces, Es3, Inc., a Nevada corporation ("Es3"), and
certain stockholders of Es3 (the "Es3 Stockholders"), wherein the Company was to
acquire Es3 in exchange for the issuance of approximately  19,414,188  shares of
the Company's common stock to the Es3  Stockholders,  Crown Partners and certain
consultants  (the  "Share  Exchange").  In  addition,  Es3  will  pay a total of
$500,000 to Crown in exchange for Crown  assuming all the debts and  liabilities
of the Company as well as in satisfaction of debts owed by the Company to Crown.
On July 19,  2005,  the  Share  Exchange  transaction  closed  (the  "Closing"),
pursuant  to which the then  current  Board of  Directors  resigned  in favor of
directors nominated by Es3.

         Pursuant to the terms of the  Exchange  Agreement,  the Company has now
acquired  17,029,537 shares of the outstanding  capital stock of Es3 in exchange
for the Company's  issuance to the Es3 Stockholders of 17,029,537  shares of the
Company's  common stock. In connection  with the Exchange  Agreement the Company
also  issued  905,438  shares  to  Crown  Partners  and  400,000  shares  to two
individuals that provided  consulting and advisory  services to the Company (the
"Consultants").  The issuance of the Company's shares of common stock to the Es3
Stockholders,  Crown Partners and the Consultants  was exempt from  registration
under the  Securities  Act of 1933, as amended  ("Securities  Act")  pursuant to
Section 4(2) thereof.  Following the Closing of the Share Exchange,  the Company
has a total of  18,413,546  shares of common stock issued and  outstanding,  and
there remain 1,079,213 shares of Es3's outstanding common stock that have yet to
be  exchanged  for  the  Company's  shares.  Under  the  terms  of the  Exchange
Agreement,  holders of those shares have 90 days  following the Closing in which
to tender them for exchange.

<PAGE>

PLAN OF OPERATIONS

         Es3 is newly formed  corporation  that was established in February 2005
to  engage  in the  business  of  manufacturing  and  distributing  a  range  of
decorative  stone  veneers  and  finishes  based  on  proprietary  Liquid  Stone
Coatings(TM)  and  Authentic  Stone  Veneers(TM).  The  coatings and veneers are
clean, cost efficient alternatives to traditional stone masonry.

         Es3  holds the  exclusive  rights to  manufacture,  use and  distribute
Liquid Stone(TM)  coatings in North America,  Central America and South America,
under an OEM License  Agreement with Liquid Stone  Manufacturing,  Inc. a Nevada
corporation and an affiliate of Es3. Liquid Stone(TM) is a water-based polymeric
stone  coating  that can be  applied to a variety of  surfaces  including  wood,
stucco, metal, concrete or asphalt to create the appearance of natural stone.

         Es3 also holds the excusive rights to  manufacture,  use and distribute
Authentic Stone  Veneer(TM)  panels in North America,  Central America and South
America,  under an OEM License  Agreement with Stone Mountain  Finishes,  Inc. a
Nevada  corporation and an affiliate of Es3.  Authentic Stone Veneer(TM)  panels
can be  formulated  in rough stone or smooth  stone  finishes.  Authentic  Stone
Veneer(TM) panels are made from proprietary materials and are molded to form the
detailed  contours  and  profiles  of natural  stone  surfaces.  The rough stone
veneers are approximately 1/10th the weight of concrete,  while the smooth stone
veneers are approximately 1/7th the weight of concrete.

         During the next twelve months Es3  anticipates  that it will incur some
research and development expenses.  The company continues to evaluate changes in
its formula for Liquid Stone(TM) to enhance the appearance and durability of its
coatings.  It is also  continuing  to  evaluate  formulas  for  Authentic  Stone
Veneers(TM),  and plans to continue testing and seek industry  certification for
its products.

         Es3 plans to market its  coatings  and veneers to both  commercial  and
residential markets. It is developing relationships with prospective dealers and
intends to employ a channel sales strategy.  Es3 currently  anticipates  initial
sales of  Liquid  Stone(TM)  will  commence  in  November  2005,  with  sales of
Authentic Stone Veneers(TM) commencing in the second or third quarter of 2006.

         A significant  component of the Es3's intermediate term growth strategy
is the acquisition and  integration of companies in related  building  materials
fields.  Es3 expects to take advantage of synergies among related  businesses to
increase  revenues and take advantage of economies of scale to reduce  operating
costs.

         Es3  currently  operates  out of leased  facilities  in San Diego,  and
presently  has two full  time  employees.  Any  additional  plant  or  equipment
expenditures,  and any significant  increase in employees will be dependent upon
the  company's  capital  resources  and the  development  of channel  and market
activity for its products.

         Es3 has not  generated any revenues  from  operations  and has incurred
approximately  $458,000 in expenses from its inception  through June 30, 2005 in
connection with its formation and initial operations. All of Es3's operations to
date have been funded by the sale of its common stock.  As of June 30, 2005, Es3
had approximately $25,000 of cash and a related party receivable of $150,000.

         Es3 anticipates that it will have to raise  additional  capital to fund
operations in the next 12 months.  To the extent that the Company is required to
raise  additional  funds to cover the costs of  operations,  it intends to do so
through  additional  public or private  offerings of debt or equity  securities.
There are no commitments  or  arrangements  for other  offerings in place and no
guaranties that any such financings would be forthcoming,  or as to the terms of
any such financings.  Any future financing may involve  substantial  dilution to
existing investors.

New Accounting Pronouncements:

         In December 2004,  the FASB,  issued a revision to SFAS 123, also known
as SFAS 123R, that amends  existing  accounting  pronouncements  for share-based
payment  transactions  in which an  enterprise  receives  employee  and  certain
non-employee  services in exchange for (a) equity  instruments of the enterprise
or (b) liabilities that are based on the fair value of the  enterprise's  equity
instruments  or that may be settled by the issuance of such equity  instruments.
SFAS 123R  eliminates  the  ability  to  account  for  share-based  compensation
transactions  using APB 25 and generally requires such transactions be accounted
for  using a  fair-value-based  method.  SFAS  123R's  effective  date  would be
applicable for awards that are granted,  modified,  become vested, or settled in
cash in annual periods  beginning  after  December 15, 2005.  SFAS 123R includes
three transition methods: one that provides for prospective  application and two
that provide for  retrospective  application.  The Company intends to adopt SFAS
123R  prospectively  commencing  in the first  quarter of the fiscal year ending
December 31, 2006.  It is expected that the adoption of SFAS 123R will cause the
company to record,  as  expense  each  quarter,  a  non-cash  accounting  charge
approximating  the fair  value of such  share  based  compensation  meeting  the
criteria outlined in the provisions of SFAS 123R.

OFF BALANCE SHEET ARRANGEMENTS

The Company does not have any off-balance  sheet  arrangements  that have or are
reasonably likely to have a current or future effect on the Company's  financial
condition,  changes in financial  condition,  revenues or  expenses,  results of
operations,  liquidity,  capital  expenditures  or  capital  resources  that  is
material to investors.

<PAGE>

ITEM 3.   CONTROLS AND PROCEDURES

We maintain controls and procedures designed to ensure that information required
to be  disclosed  in the  reports  that we file or submit  under the  Securities
Exchange Act of 1934, as amended is recorded, processed, summarized and reported
within the time periods  specified in the rules and forms of the  Securities and
Exchange  Commission.   Based  upon  their  evaluation  of  those  controls  and
procedures  performed as of the end of the period  covered by this  report,  our
chief  executive  officer and principal  financial  officer  concluded  that our
disclosure  controls and procedures  were effective as of the end of the quarter
ended June 30, 2005.

During the quarter ended June 30, 2005 there were no significant  changes in the
Company's internal controls or in other factors that could significantly  affect
these  controls  subsequent  to the  date of  their  evaluation,  including  any
corrective  actions  with  regard  to  significant   deficiencies  and  material
weaknesses.

PART II - OTHER INFORMATION


ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

         a) Exhibits

        2.1    Exchange Agreement by and among National  Healthcare  Technology,
               Inc., Special Stone Surfaces,  Es3, Inc. and certain Stockholders
               of each dated June 30,  2005  (without  exhibits  and  schedules)
               incorporated by reference to the Company's Current Report on Form
               8-K, filed with the Securities and Exchange Commission on July 5,
               2005.)

       31.1    Certification  of  Chief  Executive   Officer  pursuant  to  Rule
               13a-14(a) of the Securities Exchange Act of 1934.

       31.2    Certification  of  Chief  Financial  Officer  pursuant  to  Rule
               13a-14(a) of the Securities Exchange Act of 1934.

       32.1    Certification  of Chief  Executive  Officer and Chief  Executive
               Officer  pursuant  to Section 906 of the  Sarbanes  Oxley Act of
               2002.

         b) Reports on Form 8-K

         There were no reports on Form 8-K filed  during the  quarter  for which
this report is filed.




<PAGE>



                                   SIGNATURES

         In accordance with the requirements of the Exchange Act, the registrant
has duly  caused  this  report to be signed  on its  behalf by the  undersigned,
thereunto duly authorized.

                                        NATIONAL HEALTHCARE TECHNOLOGY, INC.


Date:  August 18, 2005                  By: /s/ ROSS LYNDON-JAMES
                                            ---------------------
                                            Ross Lyndon-James,
                                            Cheif Executive Officer


Date:  August 18, 2005                  By: /s/ BRIAN HARCOURT
                                            -------------------
                                            Brian Harcourt,
                                            Chief Financial Officer